Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in Advanced Gastric and Colorectal Cancer
NCT04067986Phase 2Unknown
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Aug 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in gastric cancer (GC), colorectal cancer (CRC), sponsored by Xiamen University Zhongshan Hospital. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04067986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067986.